Neuroprotective effect of lurasidone via antagonist activities on histamine in a rat model of cranial nerve involvement.

Neuroprotective effect of lurasidone via antagonist activities on histamine in a rat model of cranial nerve involvement.
Mol Med Rep. 2018 Feb 13;:
Authors: He B, Yu L, Li S, Xu F, Yang L, Ma S, Guo Y
Abstract
Cranial nerve involvement frequently involves neuron damage and often leads to psychiatric disorder caused by multiple inducements. Lurasidone is a novel antipsychotic agent approved for the treatment of cranial nerve involvement and a number of mental health conditions in several countries. In the present study, the neuroprotective effect of lurasidone by antagonist activities on histamine was investigated in a rat model of cranial nerve involvement. The antagonist activities of lurasidone on serotonin 5‑HT7, serotonin 5‑HT2A, serotonin 5‑HT1A and serotonin 5‑HT6 were analyzed, and the preclinical therapeutic effects of lurasidone were examined in a rat model of cranial nerve involvement. The safety, maximum tolerated dose (MTD) and preliminary antitumor activity of lurasidone were also assessed in the cranial nerve involvement model. The therapeutic dose of lurasidone was 0.32 mg once daily, administered continuously in 14‑day cycles. The results of the present study found that the preclinical prescriptions induced positive behavioral responses following treatment with lurasidone. The MTD was identified as a once daily administration of 0.32 mg lurasidone. Long‑term treatment with lurasidone for cranial nerve in...

Source: Molecular Medicine Reports - February 14, 2018 Category: Molecular Biology Tags: Mol Med Rep Source Type: research